Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT

Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 2, 2014, Pages 106-113

  Park, Eunkyung ^a,b   Hwang, Yu Mi ^c   Lee, Chan Nyoung ^a   Kim, Sujin ^d   Oh, Sun Young ^a   Kim, Young Chul ^a   Choe, Jae Gol ^a   Park, Kun Woo ^a  

^a Korea University College of Medicine   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Korea University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Dopamine transporter; Inconclusive parkinsonian features; Parkinsonism; Positron emission tomography

Indexed keywords

DOPAMINE TRANSPORTER; FP CIT 18F; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ESSENTIAL TREMOR; FEMALE; FOLLOW UP; HUMAN; MALE; PARKINSONISM; PRIORITY JOURNAL;

EID: 84901312086     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-013-0253-1     Document Type: Article

References (31)

1. Koller W, Minagan A. Treatment strategies for the management of Parkinson's disease. In: Parkinson's disease management guide. Montvale: Medical Economics Company Inc; 2001. p. 101-33.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3): 181-4.
3. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain. 1990;113(Pt 6): 1823-42.
4. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4): 861-70.
5. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18(12): 1415-23.
6. Stephenson R, Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features and detection strategies. Mov Disord. 2009;24 Suppl 2: S665-70.
7. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain. 2004;127(Pt 8): 1693-705.
8. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39(11): 1879-84.
9. 123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm. 1998;105: 1213-28.
10. 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4): 692-8.
11. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19(10): 1175-82.
12. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord. 2006;21(4): 510-4.
13. 123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord. 2007;22(9): 1278-85.
14. 123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22(16): 2346-51.
15. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45(5): 577-82.
16. Bergstrom KA, Halldin C, Lundkvist C, Swahn CG, Akerman KK, Kuikka JT, et al. Characterization of C-11 or I-123 labelled beta-CIT-FP and beta-CIT-FE metabolism measured in monkey and human plasma. Identification of two labelled metabolites with HPLC. Hum Psychopharmacol. 1996;11(6): 483-90.
17. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37(7): 1129-33.
18. 18F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007;34(4): 345-51.
19. 123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35(2): 424-38.
20. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord. 2003;18 Suppl 7: S28-33.
21. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009;24(16): 2379-85.
22. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25(3): 357-62.
23. Hambye AS, Vervaet A, Dethy S. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Commun. 2010;31(6): 583-9.
24. Chaudhuri KR, Buxton-Thomas M, Dhawan V, Peng R, Meilak C, Brooks DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry. 2005;76(1): 115-7.
25. Felicio AC, Shih MC, Godeiro-Junior C, Andrade LA, Bressan RA, Ferraz HB. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist. 2009;15(1): 6-16.
26. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006;27(12): 933-7.
27. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28(3): 266-72.
28. 123I]FP-CIT SPECT. Mov Disord. 2009;24(4): 500-8.
29. Bairactaris C, Demakopoulos N, Tripsianis G, Sioka C, Farmakiotis D, Vadikolias K, et al. Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes. J Clin Neurosci. 2009;16(2): 246-52.
30. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61(8): 1224-9.
31. Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med. 2010;51(9): 1331-4.